Haluska P - Search Results

1

Farnesyl transferase inhibitors as anticancer agents.

Haluska P, Dy GK, Adjei AA. Haluska P, et al. Eur J Cancer. 2002 Sep;38(13):1685-700. doi: 10.1016/s0959-8049(02)00166-1. Eur J Cancer. 2002. PMID: 12175684 Review.

2

Novel pharmacological agents in clinical development for solid tumours.

Dy GK, Haluska P, Adjei AA. Dy GK, et al. Among authors: haluska p. Expert Opin Investig Drugs. 2001 Dec;10(12):2059-88. doi: 10.1517/13543784.10.12.2059. Expert Opin Investig Drugs. 2001. PMID: 11772306 Review.

3

Receptor tyrosine kinase inhibitors.

Haluska P, Adjei AA. Haluska P, et al. Curr Opin Investig Drugs. 2001 Feb;2(2):280-6. Curr Opin Investig Drugs. 2001. PMID: 11816845 Review.

4

In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.

Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG, Frennesson DB, Kalli KR, Conover CA, Attar RM, Kaufmann SH, Gottardis M, Erlichman C. Haluska P, et al. Cancer Res. 2006 Jan 1;66(1):362-71. doi: 10.1158/0008-5472.CAN-05-1107. Cancer Res. 2006. PMID: 16397250

5

HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.

Haluska P, Carboni JM, TenEyck C, Attar RM, Hou X, Yu C, Sagar M, Wong TW, Gottardis MM, Erlichman C. Haluska P, et al. Mol Cancer Ther. 2008 Sep;7(9):2589-98. doi: 10.1158/1535-7163.MCT-08-0493. Epub 2008 Sep 2. Mol Cancer Ther. 2008. PMID: 18765823 Free PMC article.

6

IGF-1 receptor inhibitors in clinical trials--early lessons.

Weroha SJ, Haluska P. Weroha SJ, et al. Among authors: haluska p. J Mammary Gland Biol Neoplasia. 2008 Dec;13(4):471-83. doi: 10.1007/s10911-008-9104-6. Epub 2008 Nov 21. J Mammary Gland Biol Neoplasia. 2008. PMID: 19023648 Free PMC article. Review.

7

Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells.

Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann LC, Manjili MH, Radisky DC, Ferrone S, Knutson KL. Santisteban M, et al. Among authors: haluska p. Cancer Res. 2009 Apr 1;69(7):2887-95. doi: 10.1158/0008-5472.CAN-08-3343. Epub 2009 Mar 10. Cancer Res. 2009. PMID: 19276366 Free PMC article.

8

The pathway ahead in melanoma trials.

Miller AJ, Markovic SN, Haluska P Jr. Miller AJ, et al. Among authors: haluska p jr. Oncology (Williston Park). 2009 May;23(6):496, 498, 500. Oncology (Williston Park). 2009. PMID: 19544690 No abstract available.

9

Cixutumumab.

McKian KP, Haluska P. McKian KP, et al. Among authors: haluska p. Expert Opin Investig Drugs. 2009 Jul;18(7):1025-33. doi: 10.1517/13543780903055049. Expert Opin Investig Drugs. 2009. PMID: 19548856 Free PMC article. Review.

10

Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy.

Hendrickson AW, Haluska P. Hendrickson AW, et al. Among authors: haluska p. Curr Opin Investig Drugs. 2009 Oct;10(10):1032-40. Curr Opin Investig Drugs. 2009. PMID: 19777391 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results